Coya Therapeutics Inc (COYA)

Form 8-K - Current report

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance...

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT Will be moderated by Solomon Wilcots and feature discussion and...

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded...

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance...

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that...

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with...